SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

The RE crypto token is generating significant buzz and high trading volume as investors react to its recent listings on major platforms and its institutional focus on decentralized reinsurance. Community members are actively debating its long-term potential as a real-world asset, with many closely monitoring price action and supply constraints while sharing ambitious, high-target outlooks.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is attracting significant community attention due to its strategic focus on autonomous AI agent infrastructure and a high-profile partnership with Google Cloud. While some investors are actively accumulating the token as a long-term play on the AI narrative, others remain cautious, debating the impact of token supply dynamics and the broader volatility of the altcoin market.

Chip

Chip is currently trending as a prominent AI infrastructure play, with the community actively debating its potential as a GPU-backed lending protocol versus concerns over volatility and insider selling. Investors are closely monitoring its performance as they weigh the project's real-world use case in financing AI hardware against the risks typical of early-stage, high-beta crypto assets.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant selling pressure as investors grapple with concerns over the Exact Sciences integration, potential litigation, and broader sector rotation out of defensive healthcare stocks. While the community is debating whether the stock represents a deep-value opportunity or a long-term trap, sentiment remains divided between those expecting a structural rebound from multi-year support levels and those anticipating further downside.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as investors react to extreme volatility in the natural gas market, fueled by persistent geopolitical tensions in the Middle East and ongoing uncertainty regarding supply routes. The community is actively debating the impact of these macro events versus technical factors like contango and leveraged decay, with many traders focusing on the short-term impact of weekly storage reports on price swings.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as traders debate its potential as an AI-native infrastructure play, with community members actively discussing its role in the agentic economy and long-term utility versus short-term price volatility. Discussions are focused on its technical integrations, such as chain abstraction and AI agent capabilities, as investors weigh these structural developments against a broader, grinding crypto market.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

MRK is trending as investors react to its latest quarterly results, where strong growth in Keytruda sales helped offset declines in Gardasil, while the market also processes the implications of the company's recent strategic acquisitions. The community is actively debating the stock's long-term growth potential and pipeline execution as it navigates a challenging regulatory environment and prepares for upcoming patent expirations.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is experiencing heightened market activity as investors weigh record-breaking contract wins against ongoing concerns regarding the federal government's long-term reliance on private detention facilities. The stock remains a focal point for the community as they actively debate the potential for future asset sales, the impact of shifting DHS immigration policies, and the implications of founder George Zoley's return to the CEO role.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARK Innovation ETF is seeing intense community debate following recent portfolio shifts, as investors weigh ongoing skepticism regarding its long-term performance against high-conviction buys in emerging tech and space sectors. Traders are closely monitoring the fund's technical breakout attempts while balancing excitement over new holdings against frustration with historical volatility.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is trending as investors weigh significant volatility and divergent opinions surrounding the company's shift from low-margin hardware procurement toward higher-margin AI systems integration. While some community members are bullish on the firm's strategic focus and potential for expansion within the data center ecosystem, others express frustration over revenue fluctuations, limited partner concentration, and management's communication style.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization ofread more...

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nurix Stock Up 29% in a Month: Here's What You Should Know

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.

Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced...

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Bullish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GILDGilead Sciences, Inc.

Fundamentals

Latest GILD News